Insmed (INSM) Short term Debt (2012 - 2024)

Insmed's (INSM) quarterly Short term Debt came in at $224.4 million in Q2 2024, little changed quarter-over-quarter from $224.2 million in Q1 2024.

Insmed (INSM) Short term Debt (2012 - 2024) Analysis & Trends

Insmed's Short term Debt history runs 6 years deep, the most recent figure standing at $224.4 million for Q2 2024.

On a quarterly basis, Short term Debt changed N/A year-over-year to $224.4 million in Q2 2024; TTM through Jun 2024 was $224.4 million, a N/A change from a year earlier, with the FY2015 full-year figure at $3.1 million, changed N/A from the prior year.
Short term Debt was little changed at $224.4 million in Q2 2024 per INSM's latest filing, from $224.2 million in the prior quarter.
Across five years, Short term Debt topped out at $224.4 million in Q2 2024 and bottomed at $224.2 million in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Insmed	23.26 Bn	22.03 Bn	258.54 Mn

Download Data